Anti-tim-3 antigen antibody or antibody derivative, and use thereof
US-2024391997-A1 · Nov 28, 2024 · US
Anti-glycoprotein VI scFv fragment for treatment of thrombosis
US9045540B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9045540-B2 |
| Application number | US-201213724134-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 21, 2012 |
| Priority date | Oct 26, 2006 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly 4 Ser) 3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light chains complementary determining regions 1, 2 and 3, and preferably humanized functional variants such as the humanized scFv fragments represented by SEQ ID NO:28 or SEQ ID NO:47. The invention also relates to nucleic acids encoding such a scFv fragment, expression vectors and host cells to produce such a scFv fragment, as well as therapeutic uses of such a scFv fragment.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated antibody directed against human glycoprotein VI, comprising, either: (i) a VH domain of SEQ ID NO:26, and a VL domain, or, (ii) a VH domain and a VL domain selected from the group consisting of SEQ ID NO:27 and SEQ ID NO:46. 2. The isolated antibody according to claim 1 , which does not comprise an antibody constant region. 3. The isolated antibody of claim 1 , comprising a VH domain of SEQ ID N…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9045540B2 cover?
- The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly 4 Ser) 3 peptide and followed by a “c-myc” flag, represented by SEQ ID NO:1. The invention also concerns functional variants of said scFv 9O12.2 fragment with identical heavy and light cha…
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med
- What technology area does this patent fall under?
- Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).